



31 May 2024

## **ASX ANNOUNCEMENT (ASX:CBL)**

### **CEO Jeremy Steele to Speak at United Nations AI for Good Summit**

Control Bionics Limited (ASX: CBL) is pleased to announce that our CEO, Jeremy Steele, has been invited to speak at the United Nations AI for Good Summit in Geneva on 31 May 2024. This prestigious event brings together global leaders in artificial intelligence to discuss the latest advancements and applications of AI for the benefit of humanity.

Mr. Steele will be addressing the topic of AI for assistive technology, showcasing the impact and potential of our cutting-edge innovations in this field. He will also be providing live demonstrations of our latest device, the NeuroStrip®, highlighting its revolutionary capabilities as a universal physiological measuring device with the capabilities of providing high fidelity data into AI models.

In addition to his presentation at the summit, Mr. Steele has been actively engaging with suppliers and potential distributors in Europe. These meetings are a strategic part of our plan to expand our market presence and foster growth in the European region.

The NeuroStrip® represents the latest advancement in our technology portfolio, offering a miniaturized, wearable EMG device that opens new possibilities in various sectors, including health diagnostics, sports performance, and rehabilitation.

Control Bionics is dedicated to developing innovative solutions that improve the quality of life for individuals with communication challenges. Our participation in the AI for Good Summit underscores our commitment to leveraging AI to create meaningful and positive impacts on society.

This announcement was authorized by CBL CEO Jeremy Steele.

### **About Control Bionics:**

Control Bionics is a medical device company assisting patients whose ability to communicate verbally or via text and social media is compromised by illnesses such as Motor Neurone Disease (MND) and Amyotrophic Lateral Sclerosis (ALS). Our core patented NeuroNode technology is a wireless wearable device that detects minute signals sent from the brain to any skeletal muscle and is captured as EMG (Electromyography) output. This output is then sent wirelessly via the NeuroNode to a personal computer, enabling speech and other computer controlled functions like email and texting. Our technology is integrated with eye gaze technology whereby the eye gaze enables a cursor to be moved about a computer screen, driven much like a mouse, and the NeuroNode acts as like the mouse button. Control Bionics is the only such product to harness three modalities – touch, eye and NeuroNode control – which combined yield unique benefits in terms of the ability of patients to express themselves with significantly faster speed and less fatigue.

Control Bionics recently extended its offering to mobility with the launch of DROVE – the autonomous wheelchair module. DROVE allows powered users the independence to operate their wheelchairs in their own homes for the first time.

Control Bionics is currently commercialising its most recent advancement in its technology, the NeuroStrip®. This wearable, miniaturised EMG device provides the business with the opportunity to enter new markets such as health diagnostics, sports performance and rehabilitation to name only a few potential markets.

Control Bionics operates in North America, Australia, Singapore and Japan.

## **Investors and Media**

Jeremy Steele – CEO and Managing Director  
[jsteele@controlbionics.com](mailto:jsteele@controlbionics.com)

Brett Crowley - Company Secretary  
[brettcrowley@controlbionics.com](mailto:brettcrowley@controlbionics.com)

## **Investor Relations:**

Joe Durak  
Executive Director & Founder  
Lynx Advisors  
[joe@lynxadvisors.com.au](mailto:joe@lynxadvisors.com.au)  
+61 414 465 582

For further information visit the website: <https://www.controlbionics.com/>